<DOC>
	<DOCNO>NCT01711242</DOCNO>
	<brief_summary>The objective trial compare disease-free survival adjuvant XELOX alone vs XELOX concurrent capecitabine radiotherapy curatively resect gastric cancer patient D2 dissection .</brief_summary>
	<brief_title>Trial Adjuvant XELOX Chemotherapy Concurrent Capecitabine Radiotherapy Resected Gastric Carcinoma</brief_title>
	<detailed_description>Gastric cancer one common malignancy China . Complete surgical resection potentially curative therapy available patient gastric cancer . However , overall survival result remain unsatisfactory . The main factor accounting high mortality rate relapse surgical resection . During past decade , principle combined modality treatment develop applied gastric cancer . Radiation therapy plus concurrent chemotherapy demonstrate able achieve significant improvement overall disease-free survival accord Intergroup Trial 0116/Southwest Oncology Group 9008 . Nevertheless , result Intergroup Trial 0116 study challenge fact surgical treatment apply trial gastrectomy limit lymph node dissection ( D0 D1 ) 90 % case . Therefore , debatable whether adjuvant chemoradiation therapy confer survival benefit patient extensive lymph node dissection . In ARTIST study , addition concurrent capecitabine radiotherapy capecitabine cisplatin chemotherapy significantly reduce recurrence curative resection D2 lymph node dissection gastric cancer . In subgroup analysis patient positive pathologic lymphnodes , statistically significant prolongation disease-free survival concurrent treatment arm compare chemotherapy alone arm . Furthermore , CLASSIC study show XELOX ( oxaliplatin/capecitabine ) combination give adjuvant chemotherapy stage II III patient D2 surgery could achieve significant survival benefit . The standard treatment modality gastric cancer D2 dissection still disputable . Thus , assessment effect adjuvant sequence chemoradiotherapy D2 resect gastric cancer essential .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically proven gastric cancer ; ≥ D2 resection Stage T3、4/N+ 18 ≤ age ≤ 75 Eastern Cooperative Oncology Group 02 No distant metastasis Adequate bone marrow function ( absolute neutrophil count≥ 1,500/ul , blood platelet≥ 100,000/ul , haemoglobin≥ 10g/dl ) Adequate renal function ( serum creatinine ≤ 1.5mg/dl ) Adequate liver function ( serum bilirubin ≤ 1.5mg/dl , aspartate aminotransferase/alanine aminotransferase ≤ 3 time ( normal value ) Written inform consent Previous history immunotherapy , chemotherapy , radiotherapy gastric cancer ; Active infection require antibiotic ; Pregnant , lactate woman ; Psychiatric illness , epileptic disorder ; Concurrent systemic illness appropriate chemotherapy ; Resection margin ( + ) ; History malignancy within 5 year except nonmelanoma skin cancer , cervix situ carcinoma ; D0 , D1 resection ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>gastric cancer</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>postoperative therapy</keyword>
	<keyword>chemotherapy</keyword>
</DOC>